| Literature DB >> 26957125 |
Luciano Mignini1, Rita Champaneria2, Ekaterina Mishanina3, Khalid S Khan4.
Abstract
BACKGROUND: When generating guidelines, quality of the evidence is tabulated to capture its several domains, often using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. We developed a graphic display to capture deficiencies, outliers and similarities across comparisons contained in GRADE tables.Entities:
Mesh:
Year: 2016 PMID: 26957125 PMCID: PMC4784278 DOI: 10.1186/s12978-016-0130-3
Source DB: PubMed Journal: Reprod Health ISSN: 1742-4755 Impact factor: 3.223
The features of evidence grading captured in a GRADE plot (adapted from Evid Based Med 2011;16:65-9)
| Grade | Design | Risk of bias | Inconsistency | Indirectness | Effect size | Evidence Quality |
|---|---|---|---|---|---|---|
| Studies are either described as randomised-control trials (RCTs) or observational. | Explains the limitations of the study based on assessment of blinding and allocation process, follow-up and withdrawals, scarcity of data, other methodological concerns e.g. incomplete reporting, subjective outcomes. | Inconsistencies due to unexplained (statistical) heterogeneity. The same weakness is only downgraded once. | Presence of indirectness in the PICO elements that affect the generalisability of participants and outcomes from each study to population of interest. | Relates to imprecision of the estimated effect based on the reported odds ratios or relative risks or mean differences for comparison. This is based on the confidence intervals, sample size and number of events. | ||
| High | Randomised controlled trial | No problems | All/most studies show similar results with or inconsistency across studies is explained by a dose response | Population and outcomes broadly generalisable | Effect size more than 5 or less than 0.2 for all studies/meta-analyses included in comparison and significant | |
| Moderate | Lack of agreement between studies (e.g. statistical heterogeneity between RCTs, conflicting results) | Effect size more than 2 or less than 0.5 for all studies/meta-analyses included in comparison and significant | ||||
| Low/Very low | Controlled observational study | Problem with 2 or more elements | Serious lack of agreement between studies | Some problem with 2 or more elements | Not all effect sizes more than 2 or less than 0.5 and significant; or if effects observed not significant | |
| Examplea: Thiamine vs Placebo for Pelvic Pain | Randomised trial | No limitations | Consistent | Indirect | Precise | Moderate |
| Initially assigned a high strength level | → No Change | → No change | → Relegation | → No change | ┘ |
abased on evidence profile shown in Fig. 1 and BMJ 2012;344:e3011 doi:10.1136/bmj.e3011
Fig. 1Effect of various treatments on pelvic pain: Graphic overview of evidence quality. Each graph represents the quality domains shown on concentric spokes. Starting from 12 o’clock and moving clockwise these are design, risk of bias, inconsistency of results, indirectness of participants, and outcomes and effect size [12]. For each of the spokes, the length represents the magnitude of quality adapting the scoring system used for Clinical Evidence reviews ( http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665072.html ). The block shapes, formed by joining the lengths of the spokes, colour coded to represent the overall quality of evidence as follows: Green = high quality evidence; yellow = moderate quality; and red = low or very low quality. See main text of our Clinical Evidence review [14] for details. NSAIDs = non steroidal anti inflammatory drugs TENS = transcutaneous electric nerve stimulation LUNA = laparoscopic uterine nerve ablation. * The lack of a clinically meaningful effect of LUNA for dysmenorrhoea has been confirmed through an individual patient data meta-analysis [6]
Fig. 2Comparison of accuracy and time taken to interpret equivalent Grade tables (above) and graphs (below)